ATE249824T1 - Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a - Google Patents

Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a

Info

Publication number
ATE249824T1
ATE249824T1 AT97926449T AT97926449T ATE249824T1 AT E249824 T1 ATE249824 T1 AT E249824T1 AT 97926449 T AT97926449 T AT 97926449T AT 97926449 T AT97926449 T AT 97926449T AT E249824 T1 ATE249824 T1 AT E249824T1
Authority
AT
Austria
Prior art keywords
mla
monophosphoryl lipid
type
hypersensitivity
treating hypersensitivity
Prior art date
Application number
AT97926449T
Other languages
English (en)
Inventor
Jerry Dolovich
J Terry Ulrich
Jean S Marshall
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE249824T1 publication Critical patent/ATE249824T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT97926449T 1996-05-14 1997-05-08 Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a ATE249824T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/645,672 US5762943A (en) 1996-05-14 1996-05-14 Methods of treating type I hypersensitivity using monophosphoryl lipid A
PCT/US1997/007965 WO1997042947A1 (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid a

Publications (1)

Publication Number Publication Date
ATE249824T1 true ATE249824T1 (de) 2003-10-15

Family

ID=24589990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926449T ATE249824T1 (de) 1996-05-14 1997-05-08 Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a

Country Status (11)

Country Link
US (1) US5762943A (de)
EP (1) EP0914114B1 (de)
JP (1) JP4105230B2 (de)
AT (1) ATE249824T1 (de)
AU (1) AU3121497A (de)
CA (1) CA2252604C (de)
DE (1) DE69724970T2 (de)
DK (1) DK0914114T3 (de)
ES (1) ES2205231T3 (de)
PT (1) PT914114E (de)
WO (1) WO1997042947A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086928B2 (ja) * 1997-02-13 2008-05-14 大日本住友製薬株式会社 タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9724531D0 (en) * 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
WO2000003744A2 (en) * 1998-07-14 2000-01-27 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a
EP1671646A3 (de) * 1998-09-18 2007-08-29 Dynavax Technologies Corporation Verfahren zur Behandlung von IgE- assoziierten Krankheiten und Zusammensetzungen zur Verwendung in diesen Verfahren
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
WO2000069456A2 (en) * 1999-05-13 2000-11-23 American Cyanamid Company Adjuvant combination formulations
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
CN1606446A (zh) * 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
GB0120150D0 (en) * 2001-08-17 2001-10-10 Glaxosmithkline Biolog Sa Novel compounds
DE10359351A1 (de) * 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
TR201807756T4 (tr) * 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
EP3305319A1 (de) * 2010-04-30 2018-04-11 Allovate, LLC Verfahren und artikel zur verhinderung oder verringerung des risikos der entwicklung eines hyperallegenen immunsystems
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20160030459A1 (en) * 2014-01-21 2016-02-04 Immune Design Corp. Compositions and methods for treating allergic conditions
CA2979523A1 (en) * 2015-05-01 2016-11-10 Nitto Denko Corporation Allergy vaccine composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (de) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmazeutische Präparate
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
KR900701304A (ko) * 1988-05-05 1990-12-01 루이즈 츄이 콜린스 에이미 사람 및/또는 동물용 알레르겐 탈감작제
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
JP2838800B2 (ja) * 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
WO1993015766A1 (en) * 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens

Also Published As

Publication number Publication date
US5762943A (en) 1998-06-09
JP2000510844A (ja) 2000-08-22
PT914114E (pt) 2004-02-27
EP0914114B1 (de) 2003-09-17
CA2252604A1 (en) 1997-11-20
JP4105230B2 (ja) 2008-06-25
DE69724970T2 (de) 2004-07-22
EP0914114A1 (de) 1999-05-12
CA2252604C (en) 2009-09-08
ES2205231T3 (es) 2004-05-01
AU3121497A (en) 1997-12-05
DE69724970D1 (de) 2003-10-23
WO1997042947A1 (en) 1997-11-20
DK0914114T3 (da) 2003-10-20

Similar Documents

Publication Publication Date Title
DE69724970D1 (de) Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE205713T1 (de) Perkutane behandlung mit mastzelldegranulatoren zur behandlung von reizstoffüberempfindlichkeit
MX9800684A (es) Formulacion de proteinas liofilizadas isotonicas estables.
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
NZ504894A (en) Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
DE69836268D1 (de) Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen
DE69800716D1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
Brady et al. Autoregulation of periodontal ligament cell phenotype and functions by transforming growth factor-β1
DE69635496D1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
NO933261L (no) Blanding til forsterkning av immunforsvaret
BR9507846A (pt) Composição farmacéutica estável e fortemente concentrada de principio ativo da classe dos taxóides escolhido entre o docetaxol ou os derivados do docetaxol processo de preparação desta composição e utilização de uma solução congelada ou liofilizada
ATE219683T1 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
ATE352634T1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
Vischer Mitogenic factors produced by lymphocyte activation: effect on T-and B-cells
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
Dhalla et al. Calcium binding and ATPase activities of heart sarcolemma
NO955085D0 (no) Androstansteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
Hartmann INDUCTION OF A HEMOLYSIN RESPONSE IN VITRO: II. Influence of the Thymus-Derived Cells During the Development of the Antibody-Producing Cells
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
NO955084L (no) Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914114

Country of ref document: EP